Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 12;12(12):CD010790.
doi: 10.1002/14651858.CD010790.pub3.

Laser therapy for retinopathy in sickle cell disease

Kay Thi Myint  1 , Soumendra Sahoo  2 , Aung Win Thein  3 , Soe Moe  4 , Han Ni  5
Affiliations

Laser therapy for retinopathy in sickle cell disease

Kay Thi Myint et al. Cochrane Database Syst Rev. .

Abstract

Background: Sickle cell disease (SCD) includes a group of inherited haemoglobinopathies affecting multiple organs including the eyes. Some people with SCD develop ocular manifestations. Vision-threatening complications are mainly due to proliferative sickle retinopathy, which is characterised by proliferation of new blood vessels. Laser photocoagulation is widely applicable in proliferative retinopathies. It is important to evaluate the efficacy and safety of laser photocoagulation in the treatment of proliferative sickle retinopathy (PSR) to prevent sight-threatening complications.

Objectives: To evaluate the effectiveness of various techniques of laser photocoagulation therapy in SCD-related proliferative retinopathy.

Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register, compiled from electronic database searches and handsearching of journals and conference abstract books. Date of last search: 4 July 2022. We also searched the following resources (26 June 2022): Latin American and Caribbean Health Science Literature Database (LILACS); WHO International Clinical Trials Registry Platforms (ICTRP); and ClinicalTrials.gov.

Selection criteria: Randomised controlled trials comparing laser photocoagulation to no treatment in children and adults with SCD.

Data collection and analysis: Two review authors independently assessed eligibility and risk of bias of the included trials; we extracted and analysed data, contacting trial authors for additional information. We assessed the certainty of the evidence using the GRADE criteria.

Main results: We included three trials (414 eyes of 339 children and adults) comparing the efficacy and safety of laser photocoagulation to no therapy in people with PSR. There were 160 males and 179 females ranging in age from 13 to 67 years. The trials used different laser photocoagulation techniques; one single-centre trial employed sectoral scatter laser photocoagulation using an argon laser; a two-centre trial employed feeder vessel coagulation using argon laser in one centre and xenon arc in the second centre; while a third trial employed focal scatter laser photocoagulation using argon laser. The mean follow-up periods were 21 to 32 months in one trial, 42 to 47 months in a second, and 48 months in the third. Two trials had a high risk of allocation bias due to the randomisation method for participants with bilateral disease; the third trial had an unclear risk of selection bias. One trial was at risk of reporting bias. Given the unit of analysis is the eye rather than the individual, we chose to report the data narratively. Using sectoral scatter laser photocoagulation, one trial (174 eyes) reported no difference between groups for complete regression of PSR: 30.2% in the laser group and 22.4% in the control group. The same trial also reported no difference between groups in the development of new PSR: 34.3% of lasered eyes and 41.3% of control eyes (very low-certainty evidence). The two-centre trial using feeder vessel coagulation, only presented data at follow-up for one centre (mean period of nine years) and reported the development of new sea fan in 48.0% in the treated and 45.0% in the control group; no statistical significance (P = 0.64). A third trial reported regression in 55% of the laser group versus 28.6% of controls and progression of PSR in 10.5% of treated versus 25.7% of control eyes. We graded the evidence for these two primary outcomes as very low-certainty evidence. The sectoral scatter laser photocoagulation trial reported visual loss in 3.0% of treated eyes (mean follow-up 47 months) versus 12.0% of controlled eyes (mean follow-up 42 months) (P = 0.019). The feeder vessel coagulation trial reported visual loss in 1.14% of the laser group and 7.5% of the control group (mean follow-up 26 months at one site and 32 months in another) (P = 0.07). The focal scatter laser photocoagulation trial (mean follow-up of four years) reported that 72/73 eyes had the same visual acuity, while visual loss was seen in only one eye from the control group. We graded the certainty of the evidence as very low. The sectoral scatter laser trial detected vitreous haemorrhage in 12.0% of the laser group and 25.3% of control with a mean follow-up of 42 (control) to 47 months (treated) (P ≤ 0.5). The two-centre feeder vessel coagulation trial observed vitreous haemorrhage in 3.4% treated eyes (mean follow-up 26 months) versus 27.5% control eyes (mean follow-up 32 months); one centre (mean follow-up nine years) reported vitreous haemorrhage in 1/25 eyes (4.0%) in the treatment group and 9/20 eyes (45.0%) in the control group (P = 0.002). The scatter laser photocoagulation trial reported that vitreous haemorrhage was not seen in the treated group compared to 6/35 (17.1%) eyes in the control group and appeared only in the grades B and (PSR) stage III) (P < 0.05). We graded evidence for this outcome as low-certainty. Regarding adverse effects, only one occurrence of retinal tear was reported. All three trials reported on retinal detachment, with no significance across the treatment and control groups (low-certainty evidence). One trial reported on choroidal neovascularization, with treatment with xenon arc found to be associated with a significantly higher risk, but visual loss related to this complication is uncommon with long-term follow-up of three years or more. The included trials did not report on other adverse effects or quality of life.

Authors' conclusions: Our conclusions are based on the data from three trials (two of which were conducted over 30 years ago). Given the limited evidence available, which we assessed to be of low- or very low-certainty, we are uncertain whether laser therapy for sickle cell retinopathy improves the outcomes measured in this review. This treatment does not appear to have an effect on clinical outcomes such as regression of PSR and development of new incidences. No evidence is available assessing efficacy in relation to patient-important outcomes (such as quality of life or the loss of a driving licence). Further research is needed to examine the safety of laser treatment compared to other interventions such as intravitreal injection of anti-vascular endothelial growth factors (VEGFs) . Patient-important outcomes as well as cost-effectiveness should be addressed.

PubMed Disclaimer

Conflict of interest statement

All authors: none known.

Figures

1
1
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included trial.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Farber 1991 {published data only}
    1. Farber MD, Jampol LM, Fox P, Moriarty BJ, Acheson RW, Rabb MF, et al. A randomized clinical trial of scatter photocoagulation of proliferative sickle cell retinopathy. Archives of Ophthalmology 1991;109(3):363-7. 5500100000000467 - PubMed
    1. Fox PD, Minninger K, Forshaw ML, Vessey SJ, Morris JS, Serjeant GR. Laser photocoagulation for proliferative retinopathy in sickle haemoglobin C disease. Eye (London, England) 1993;7(Pt 5):703-6. 5500100000000604 - PubMed
    1. Jampol LM, Farber M, Fox P, Moriarty B, Acheson R, Rabb M, et al. Photocoagulation of proliferative sickle cell retinopathy. The Macula Society 1991:26. - PubMed
    1. Jampol LM, Farber M, Rabb MF, Serjeant G. An update on techniques of photocoagulation treatment of proliferative sickle cell retinopathy. Eye (London, England) 1991;5:260-3. 5500100000000478 - PubMed
Jampol 1983 {published data only}
    1. Condon P, Jampol LM, Farber MD, Rabb M, Serjeant G. A randomized clinical trial of feeder vessel photocoagulation of proliferative sickle cell retinopathy. II. Update and analysis of risk factors. Ophthalmology 1984;91(12):1496-8. 5500100000000214 - PubMed
    1. Jacobson MS, Gagliano DA, Cohen SB, Rabb MF, Jampol LM, Farber MD, et al. A randomized clinical trial of feeder vessel photocoagulation of sickle cell retinopathy. A long-term follow-up. Ophthalmology 1991;98(5):581-5. 5500100000000475 - PubMed
    1. Jampol LM, Condon P, Farber M, Rabb M, Ford S, Serjeant G. A randomized clinical trial of feeder vessel photocoagulation of proliferative sickle cell retinopathy. I. Preliminary results. Ophthalmology 1983;90(5):540-5. 5500100000000178 - PubMed
    1. Jampol LM, Farber M, Rabb MF, Serjeant G. An update on techniques of photocoagulation treatment of proliferative sickle cell retinopathy. Eye (London, England) 1991;5:260-3. 5500100000000478 - PubMed
Sayag 2008 {published data only}
    1. Sayag D, Binaghi M, Souied E, Pawlak D, Galacteros F, Coscas G, et al. Peripheral retinal scatter photocoagulation for the treatment of proliferative sickle retinopathy: a prospective clinical trial with new sea fan classification. European Journal of Ophthalmology 2008;18(2):248-54. [CENTRAL: 638176;CRS:5500050000000040;CRSREF:2762960] [PMID: ] - PubMed
    1. Sayag D, Binaghi M, Souied E, Pawlak D, Galacteros F, Coscas G, et al. Peripheral retinal scatter photocoagulation for the treatment of proliferative sickle retinopathy: is it always indispensable? In: IOVS. Vol. AVO E-Abstract:5266. 2004. [CENTRAL: 598655:CRS:5500050000000039;CRSREF:2672961]

References to studies excluded from this review

Acheson 1991 {published data only}
    1. Acheson RW, Fox PD, Chuang EL, Serjeant GR. Treatment of iatrogenic choriovitreal neovascularisation in sickle cell disease. British Journal of Ophthalmology 1991;75(12):729-30. 5500100000000502 - PMC - PubMed
Berman 1989 {published data only}
    1. Berman DH, Gombos GM. Proliferative vitreoretinopathy: does oral low-dose colchicine have an inhibitory effect? A controlled study in humans. Ophthalmic Surgery 1989;20(4):268-72. [CENTRAL: CN-00060553] [PMID: ] - PubMed
Condon 1974 {published data only}
    1. Condon PI, Serjeant GR. Photocoagulation in sickle cell retinopathy [abstract]. In: Commonwealth Caribbean Medical Research Council, 19th Scientific Meeting; 1974 April 26-29; Mona, Jamaica. 1974:1-2. 5500100000001736
Lemaire 2013 {published data only}
    1. Lemaire C, Lamarre Y, Lemonne M, Waltz X, Chahed S, Cabot F, et al. Severe proliferative retinopathy is associated with blood hyperviscosity in sickle cellhemoglobin-C disease but not in sickle cell anemia. Clinical Hemorheology and Microcirculation 2013;55:205-11. [DOI: 10.3233/CH-2012-1622] - DOI - PMC - PubMed
Osuji 2003 {published data only}
    1. Osuji NC, Majone B, Lumley H, Day A, O'Sullivan E, De Alwis D. Screening for sickle retinopathy: a new, rapid and effective approach using the panoramic 200 panretinal camera [abstract]. British Journal of Haematology 2003;121 Suppl 1:43-4. 5500100000002620

Additional references

Abiose 1978
    1. Abiose A, Lesi FE. Ocular findings in children with homozygous sickle cell anaemia in Nigeria. Journal of Paediatric Ophthalmology and Strabismus 1978;15(2):92-5. - PubMed
Ballas 2010
    1. Ballas SK, Leiff S, Benjamin LJ, Dampier CD, Heeney MM, Hoppe C, et al. Definitions of phenotypic manifestations of sickle cell disease. American Journal of Haematology 2010;85(1):6-13. [DOI: 10.1002/ajh.21550] - DOI - PMC - PubMed
Ballas 2012
    1. Ballas SK, Kesen MR, Goldberg MF, Lutty GA, Dampier K, Osunkwo I, et al. Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. Scientific World Journal http://www.hindawi.com/journals/tswj/2012/949535 (accessed 15 April 2013). [DOI: 10.1100/2012/949535] - DOI - PMC - PubMed
Castro 1999
    1. Castro O. Management of sickle cell disease: recent advances and controversies. British Journal of Haematology 1999;107(1):2-11. - PubMed
Cohen 1986
    1. Cohen SB, Fletcher ME, Goldberg MF, Jednock NJ. Diagnosis and management of ocular complications of sickle haemoglobinopathies: part IV. Ophthalmic Surgery 1986;17(5):312-5. - PubMed
Condon 1972
    1. Condon PI, Serjeant GR. Ocular findings in homozygous sickle cell anaemia in Jamaica. American Journal of Ophthalmology 1972;73(4):533-4. - PubMed
Condon 1974a
    1. Condon PI, Gray R, Serjeant GR. Ocular findings in children with sickle cell haemoglobin C disease in Jamaica. British Journal of Ophthalmology 1974;58(7):644-9. - PMC - PubMed
Condon 1974b
    1. Condon PI, Serjeant GR. Photocoagulation and diathermy in the treatment of proliferative sickle retinopathy. British Journal of Ophthalmology 1974;58(7):650-62. - PMC - PubMed
Cruess 1983
    1. Cruess AF, Stephens RF, Magargal LE, Brown GC. Peripheral circumferential retinal scatter photocoagulation for treatment of proliferative sickle retinopathy. Ophthalmology 1983;90(3):272-8. - PubMed
Deeks 2021
    1. Deeks J, Higgins JP, Altman D (editors). Deeks JJ, Higgins JP, Altman DG. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 [updated February 2021]. Cochrane, 2021.. Available fromtraining.cochrane.org/handbook/archive/v6.2..
Downes 2005
    1. Downes SM, Hambleton IR, Chuang EL, Lois N, Serjeant GR, Bird AC. Incidence and natural history of proliferative sickle cell retinopathy: observation from a cohort study. Ophthalmology 2005;112(11):1869-75. - PubMed
Elagouz 2010
    1. Elagouz M, Jyothi S, Gupta B, Sivaprasad S. Sickle cell disease and the eye: old and new concepts. Survey of Ophthalmology 2010;55(4):359-77. - PubMed
Emerson 2005
    1. Emerson GG, Lutty GA. Effects of sickle cell disease on eye: clinical features and treatment. Hematology/Oncology Clinics of North America 2005;19(5):957-73. - PubMed
Emerson 2006
    1. Emerson GE, Harlan JB, Fekrat S, Lutty GA, Goldberg MF. Hemoglobinopathies. In: Ryan SJ, editors(s). Retina. 4th edition. Vol. 2. Edinburgh: Elsevier, 2006:1429-45.
Erachulu 2006
    1. Erachulu UV, Pam VA, Akuse RM. Ocular findings in children with severe clinical symptoms of homozygous sickle cell anaemia in Kaduna, Nigeria. West African Journal of Medicine 2006;25(2):88-91. - PubMed
Evans 2014
    1. Evans JR, Michelessi M, Virgili G. Laser photocoagulation for proliferative diabetic retinopathy. Cochrane Database of Systematic Reviews 2014, Issue 11. Art. No: CD011234. [DOI: 10.1002/14651858.CD011234.pub2] - DOI - PMC - PubMed
Fox 1991
    1. Fox PD, Vessey SJ, Forshaw ML, Serjearnt GR. Influence of genotype on the natural history of untreated proliferative sickle retinopathy. British Journal of Ophthalmology 1991;75(4):229-31. - PMC - PubMed
Fox 1993
    1. Fox PD, Minninger K, Forshaw ML, Vessey SJ, Morris JS, Serjeant GR. Laser photocoagulation for proliferative retinopathy in sickle haemoglobin C disease. Eye (London, England) 1993;7(Pt 5):703-6. 5500100000000604 - PubMed
Goldbaum 1979
    1. Goldbaum MH, Fletcher RC, Jampol LM, Goldberg MF. Cryotherapy for proliferative sickle retinopathy,II: a triple freeze-thaw cycle. British Journal of Ophthalmology 1979;63(2):97-101. - PMC - PubMed
Goldberg 1971
    1. Goldberg MF. Natural history of untreated proliferative sickle retinopathy. Archives of Ophthalmology 1971;85(4):428-37. - PubMed
Goldberg 1983
    1. Goldberg MF, Jampol LM. Treatment of neovascularization, vitreous haemorrhage and retinal detachment in sickle cell retinopathy. Transactions of the New Orleans Academy of Ophthalmology 1983;31:58-81. - PubMed
Higgins 2011
    1. Higgins JP, Altman DG, Sterne JA (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. Available from www.cochrane-handbook.org.
Hirst 2012
    1. Hirst C, Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No: CD003427. [DOI: 10.1002/14651858.CD003427.pub2] - DOI - PubMed
Kimmel 1986
    1. Kimmel AS, Magagal LE, Stephens RS, Cruess AF. Peripheral circumferential retinal scatter photocoagulation for the treatment of proliferative sickle retinopathy. An update. Ophthalmology 1986;93(11):1429-34. - PubMed
Lutty 1994
    1. Lutty GA, Goldberg MF. Ophthalmologic complications. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, editors(s). Sickle Cell Disease: Basic Principle and Clinical Practice. New York: Raven Press, 1994:703-24.
Marti‐Carvajal 2012
    1. Marti-Carvajal AJ, Knight-Madden JM, Martinez-Zapata MJ. Interventions for treating leg ulcers in people with sickle cell disease. Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No: CD008394. [DOI: 10.1002/14651858.CD008394.pub2] - DOI - PubMed
Moriaty 1988
    1. Moriaty BJ, Acheson RW, Condon PI, Serjeant GR. Patterns of visual loss in untreated sickle cell retinopathy. Eye 1988;2(Pt 3):330-5. - PubMed
Myint 2013
    1. Myint KT, Sahoo S, Moe S, Ni H. Laser therapy for retinopathy in sickle cell disease. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No: CD010790. [DOI: 10.1002/14651858.CD010790] - DOI - PMC - PubMed
Penman 1994
    1. Penman AD, Talbot AF, Chuang EL, Thomas P, Serjeant GR, Bird AC. New classification of peripheral retinal vascular changes in sickle cell disease. Bnrtish Journal ofOphthalmology 1994;78:681-9. - PMC - PubMed
Rednam 1982
    1. Rednam KR, Jampol IM, Goldberg MF. Scatter retinal photocoagulation for proliferative sickle cell retinopathy. American Journal of Ophthalmology 1982;93(5):594-9. - PubMed
RevMan Web 2022 [Computer program]
    1. Review Manager Web (RevMan Web). Version 4.14.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.
Roberts 2007
    1. Roberts I, Montalembert M. Sickle cell disease as a paradigm of immigration hematology: new challenges for haematologists in Europe. Haematologica 2007;92(07):865-92. - PubMed
Seiberth 2001
    1. Seiberth V. Transscleral and transpupillary laser coagulation in proliferative sickle-cell retinopathy. Ophthalmologe 2001;98(2):199-202. - PubMed
Serjeant 2001
    1. Serjeant GR. The emerging understanding of sickle cell disease. British Journal of Haematology 2001;112(1):3-18. - PubMed
Shaikh 2008
    1. Shaikh S. Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy. Indian Journal of Ophthalmology 2008;56(3):259. - PMC - PubMed
Siqueira 2006
    1. Siqueira RC, Costa RA, Scott IU, Cintra LP, Jorge R. Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy. Acta Ophthalmologica Scandinavica 2006;84:834-5. [DOI: 10.1111/j.1600-0420.2006.00779.x] - DOI - PubMed
Virgili 2009
    1. Virgili G, Bini A. Laser photocoagulation for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No: CD004763. [DOI: 10.1002/14651858.CD004763.pub2] - DOI - PubMed
Weatherall 2001
    1. Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problems. Bulletin of the World Health Organization 2001;79(8):1-15. - PMC - PubMed

References to other published versions of this review

MYint 2013
    1. Myint KT, Sahoo S, Moe S, Ni H. Laser therapy for retinopathy in sickle cell disease. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No: CD010790. [DOI: 10.1002/14651858.CD010790] - DOI - PMC - PubMed
Myint 2015
    1. Myint KT, Sahoo S, Thein AW, Moe S, Ni H. Laser therapy for retinopathy in sickle cell disease. Cochrane Database of Systematic Reviews 2015, Issue 10. Art. No: CD010790. [DOI: 10.1002/14651858.CD010790.pub2] - DOI - PMC - PubMed

Publication types

LinkOut - more resources